Renalytix Expands Kidney Disease Testing Access in New York Through NYKHM Collaboration

Renalytix ( (GB:RENX) ) has provided an announcement.

Renalytix has announced a collaboration with New York Kidney & Hypertension Medicine (NYKHM) to expand access to its kidneyintelX.dkd testing in underserved communities in the Greater New York area. This partnership aims to provide over 2,000 patients with access to this FDA-approved prognostic test, enhancing early-stage risk assessment and personalized treatment plans for chronic kidney disease. The collaboration includes community-based provider education and patient awareness initiatives to promote early detection and management of kidney disease, potentially improving patient outcomes and quality of life.

Spark’s Take on GB:RENX Stock

According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.

Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.

To see Spark’s full report on GB:RENX stock, click here.

More about Renalytix

Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for early-stage risk assessment in patients with type 2 diabetes and chronic kidney disease stages 1-3b. Renalytix operates commercially in the United States and collaborates with large physician group practices and health systems.

Average Trading Volume: 142,295

Technical Sentiment Signal: Sell

Current Market Cap: £26.5M

For an in-depth examination of RENX stock, go to TipRanks’ Stock Analysis page.